Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus

Journal of Diabetes and its Complications

Volumn 27, Issue 3, 2013, Pages 268-273

  Fonseca, Vivian A ^a   Ferrannini, Ele ^b   Wilding, John P ^c   Wilpshaar, Wim ^d   Dhanjal, Perminder ^d   Ball, Greg ^e   Klasen, Sally ^e  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d Astellas Pharma Global Development   (Netherlands)

^e ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Diabetes; Glucose; Hyperglycemia; Ipragliflozin; Sodium glucose co transporter 2 (SGLT2) inhibitor

Indexed keywords

HEMOGLOBIN A1C; IPRAGLIFLOZIN; METFORMIN; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; GENITAL TRACT INFECTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFESTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT INFECTION; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUGS, INVESTIGATIONAL; FEMALE; FOLLOW-UP STUDIES; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MEMBRANE TRANSPORT MODULATORS; MIDDLE AGED; REPRODUCTIVE TRACT INFECTIONS; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; URINARY TRACT INFECTIONS; WEIGHT LOSS;

EID: 84876899238     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2012.11.005     Document Type: Article

References (17)

1. American Diabetes Association Standards of medical care in diabetes - 2012 Diabetes Care 35 Suppl 1 2012 S11 S63
2. C.J. Bailey, J.L. Gross, A. Pieters, A. Bastien, and J.F. List Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial Lancet 375 9733 2010 2223 2233
3. J. Bolinder, Ö. Ljunggren, J. Kullberg, L. Johansson, J. Wilding, and A.M. Kangkilde Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin Journal of Clinical Endocrinology and Metabolism 97 3 2012 1020 1031
4. G. Danaei, M.M. Finucane, Y. Lu, G.M. Singh, M.J. Cowan, and C.J. Paciorek National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 27 million participants Lancet 378 9785 2011 31 40
5. E. Ferrannini, S.J. Ramos, A. Salsali, W. Tang, and J.F. List Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial Diabetes Care 33 10 2010 2217 2224
6. J. Freijer, W. Krauwinkel, T. Kadokura, W. Zhang, A. Kaibara, and R. Smulders PK/PD model for ASP1941, a novel SGLT2 inhibitor, characterizes exposure-urinary glucose: Excretion relationship in healthy subjects and type 2 diabetes mellitus patients [abstract R6400] http://www.aapsj.org/abstracts/AM- 2010/R6400.pdf 2010 Accessed July 19, 2012
7. J.E. Gerich, and A. Bastien Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus Expert Review of Clinical Pharmacology 4 6 2011 669 683
8. T.C. Hardman, and S.W. Dubrey Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes Diabetes Therapy 2 3 2011 133 145
9. T. Kadokura, M. Saito, A. Utsuno, K. Kazuta, S. Yoshida, and S. Kawasaki Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects Diabetology International 2 4 2011 172 182
10. A. Kashiwagi, Y. Takinami, K. Kazuta, S. Yoshida, A. Utsuno, and I. Nagase Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGHTEN Study [presentation 149] http://www.abstractsonline. com/Plan/ViewAbstract.aspx?sKey=cd5f5c06-c07f-4dc8-8922-44f431e2a6bb&cKey= 604f1a50-58b9-4042-9c1c-eb00a503e4d5&mKey=%7bBAFB2746-B0DD-4110-8588- E385FAF957B7%7d 2011 Accessed July 19, 2012
11. A. Kashiwagi, A. Utsuno, K. Kazuta, S. Yoshida, and S. Kageyama ASP1941, a novel, selective SGLT2 inhibitor, was effective and safe in Japanese healthy volunteers and patients with type 2 diabetes mellitus [abstract 75-OR] http://professional.diabetes.org/Abstracts-Display.aspx?TYP=1&CID=79021 2010 Accessed July 19, 2012
12. J.F. List, V. Woo, E. Morales, W. Tang, and F.T. Fiedorek Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 32 4 2009 650 657
13. D.M. Nathan, J.B. Buse, M.B. Davidson, R.J. Heine, R.R. Holman, and R. Sherwin Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 29 8 2006 1963 1972
14. M.A. Nauck, S. Del Prato, J.J. Meier, S. Durán-García, K. Rohwedder, and M. Elze Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 34 9 2011 2015 2022
15. S.L. Schwartz, B. Akinlade, S. Klasen, D. Kowalski, W. Zhang, and W. Wilpshaar Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus Diabetes Technology & Therapeutics 13 12 2011 1219 1227
16. S.A. Veltkamp, T. Kadokura, W.J. Krauwinkel, and R.A. Smulders Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects Clinical Drug Investigation 31 12 2011 839 851
17. J.P. Wilding, V. Woo, N.G. Soler, A. Pahor, J. Sugg, and K. Rohwedder Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial Annals of Internal Medicine 156 6 2012 405 415